‹ All stocks
Liquidia
LQDA · NASDAQ · Healthcare
$27.79
▲ $27.79 (2.69%)
Day range
$26.67 – $28.53
Year range
$21.94 – $93.61
Open
$27.06
Previous close
—
Market cap
$2.47B
Volume (24h)
$2.5M
Volume (52w)
$68.25M
Performance
7D
▼ -2.98%
1M
▼ -59.80%
3M
▼ -60.98%
6M
▼ -28.48%
1Y
▲ 14.58%
YTD
▼ -11.51%
3Y
▲ 326.83%
5Y
▲ 805.11%
All-time
▲ 150.33%
Key statistics
P/E ratio
20.28
EPS (TTM)
$1.37
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
88.9M
About Liquidia
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Visit websiteCountry: United States of America
Related news
Liquidia Stock Drops 5% Amid Market Volatility
Liquidia's stock fell 5% today, reflecting broader market volatility and investor concerns. Analysts are closely monitoring the company's p…
Liquidia's Stock Plummets 48% After Patent Ruling, Options Activity Spikes
Liquidia's shares fell sharply by 48% following a patent ruling, prompting a surge in options trading. Investors are reacting to the implic…
Liquidia Stock Plummets: Key Factors Behind Today's Decline
Liquidia's stock is experiencing a significant drop today, driven by concerns over its recent FDA approval and market reactions. Investors …
Liquidia Shares Plunge Following Court Ruling in Favor of United Therapeutics
Liquidia Technologies' stock took a significant hit after a court ruled in favor of United Therapeutics in a patent dispute. The decision h…
Liquidia's Growth Potential Faces Valuation Challenges in Mid-Cap Market
Liquidia is experiencing significant growth in its sector, but its high valuation raises concerns. Investors are weighing the company's pot…
More in Healthcare
LLY Eli Lilly and Company |
$1169.60 | -1.61% |
JNJ Johnson & Johnson |
$256.48 | -0.76% |
ABBV AbbVie |
$272.42 | 0.39% |
MRK Merck & Co. |
$142.38 | -0.29% |
UNH UnitedHealth Group Incorp… |
$370.95 | -1.34% |
